Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Tiseo

PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A06Patient-Centred Approach in a Multicenter National Study (E-Lung): 405 Lung Cancer Patients and Caregivers, Nurses and Oncologists Compared

Annals of Oncology
MedicineOncologyHematology
2016English

Related publications

Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
2017English

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management
2020English

Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-positive Advanced NSCLC Patient

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Outcomes of ALK Positive Lung Cancer Patients Treated With Crizotinib or Second-Generation ALK Inhibitor: A Monoinstitutional Experience

Oncotarget
Oncology
2018English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib

Journal of Community and Supportive Oncology
OncologyHematology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy